Hosted on MSN1h
23andMe to cut 40% of workforce, end therapeutics program
23andMe went public in 2021 and grew to a market valuation of $6 billion. Since April, Wojcicki had been trying to take the ...
23andMe to reduce overall headcount by 40% of workforce
Holding “announced a business restructuring to streamline operations and reduce costs. In addition, 23andMe is discontinuing ...
23andMe cuts 40% of its workforce, discontinues all therapy programs
Genetic testing firm 23andMe said on Monday it is reducing about 40%, or 200 employees, from its workforce and discontinuing ...
DNA-testing site 23andMe to lay off 40% of its workers
The struggling genetic testing company 23andMe says it will cut 40% of its workforce, or 200 jobs, as it fights for survival.
23andMe to slash 40% of its workforce, end therapeutics program to cut costs
DNA-testing company 23andMe Holding Co. will slash its workforce by about 40% and discontinue its therapeutics program as part of a restructuring effort to cut costs, the company said Monday.
FierceBiotech8h
23andMe shutters cancer drug research programs, lays off 40% of staff
Prior to that, 23andMe’s independent directors—Roelof Botha, Patrick Chung, Sandra Hernández, Neal Mohan, Valerie Montgomery ...